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AHA- Autoimmune hemolytic anemia
CVID- Common variable immunodeﬁciencyES- Evans syndrome
ITP- Immune thrombocytopenia
PAD- Predominant antibody deﬁciency
PH- Persistent hypogammaglobulinemia
PID- Primary immunodeﬁciency
RTX- Rituximab
smB- Switched-memory BRTX. Patients with previously diagnosed malignancy or
primary immune deﬁciency (PID) were excluded.
RESULTS: We analyzed 53 children treated with RTX for
immune thrombocytopenia (n [ 36), AHA (n [ 13), and ES
(n [ 4). Median follow-up was 30 months (range, 12-48).
Thirty-two percent of patients (17 of 53) experienced PH,
deﬁned as IgG levels less than 2 SD for age at last follow-up
(>12 months after RTX). Signiﬁcantly delayed B-cell recovery
was observed in children experiencing PH (hazard ratio, 0.55;
P < .05), and 6 of 17 (35%) patients had unresolved B-cell
lymphopenia at last follow-up. PH was associated with IgA and
IgM deﬁciency, younger age at RTX use (51 vs 116 months;
P < .01), a diagnosis of AHA/ES, and better response to RTX.
Nine patients with PH (9 of 17 [53%]) were eventually diag-
nosed with a PID.
CONCLUSIONS: Post-RTX PH is a frequent condition in
children with autoimmune cytopenia; a sizable proportion of
patients with post-RTXPHwere eventually diagnosedwith a PID.
In-depth investigation for PID is therefore recommended in these
patients.  2019 American Academy of Allergy, Asthma &
Immunology (J Allergy Clin Immunol Pract 2019;-:---)
Key words: Rituximab; Hypogammaglobulinemia; Cytopenia;
Autoimmunity; Primary immunodeﬁciency
INTRODUCTION
Immune thrombocytopenia (ITP), autoimmune hemolytic
anemia (AHA), and Evans syndrome (ES) are autoimmune
conditions that can be successfully treated with immunoglobu-
lins and/or steroids, or may not require any treatment in speciﬁc
situations (ie, mild symptomatic ITP).1-6 However, when the
cytopenia is symptomatic and refractory to ﬁrst-line treatments,
rituximab (RTX), an mAb anti-CD20, can be used to deplete B
cells considered responsible for autoantibody production.7-10
The rationale for RTX rests on its speciﬁcity for B cells
expressing CD20. Because both plasma cells and pro-B cells lack
CD20 expression, they are not depleted by RTX and can fulﬁll
IgG production and B-cell immune reconstitution, respec-
tively.11 For this reason, hypogammaglobulinemia is not usually
expected after treatment with RTX. However, both a drop in
IgM, although temporary,12,13 and persistent low IgG level in
high-risk patients (eg, affected by malignant disorders) have been
reported.14,15 The role of RTX in inducing prolonged low IgG
levels is not easily discernible in these patients, because of the
heterogeneity of treatments as well as their underlying hemato-
oncological disease. Moreover, the clinical signiﬁcance of hypo-
gammaglobulinemia after RTX is unclear, because a very lowincidence of infections has been reported,16-18 although some
authors recommend immunoglobulin replacement therapy to
prevent infectious complications.19,20 A higher number of RTX
administrations and lower basal IgG levels have been associated
with a higher rate of symptomatic hypogammaglobulinemia in
adults.14 In children, data on reconstitution of B cells and IgG
levels are scarce and limited to case reports/series. However,
persistent hypogammaglobulinemia (PH) requiring immuno-
globulin replacement has been described in children with auto-
immune conditions treated with RTX.21-29 Interestingly, some
of these patients presented immunologic and clinical features
recalling common variable immunodeﬁciency (CVID), sup-
porting the hypothesis that RTX-induced B-cell perturbation can
unveil a primary immunologic disorder.30
The aim of this study was to assess the prevalence and risk
factors for PH in a cohort of children who received RTX for
autoimmune cytopenia, to assist clinicians in the surveillance and
management of these patients.METHODS
From May 2016 to January 2019 we retrospectively and pro-
spectively collected data on children who were treated with RTX for
autoimmune cytopenia (ITP, AHA, and ES) at 16 centers from the
Italian Network for Primary Immunodeﬁciency and at Great
Ormond Street Hospital (London, UK). Standard dose of single
RTX administration was 375 mg/m2. Patients younger than 18 years
at the time of treatment with RTX with at least 12 months of clinical
and immunologic follow-up were included. Children with malignant
disorders or primary immunodeﬁciency (PID) or PID-like pheno-
type (eg, autoimmune lymphoproliferative syndrome or autoim-
mune lymphoproliferative syndromeelike conditions) at the time of
RTX use were excluded. Pre-RTX and follow-up data
at þ6, þ12, þ24, þ36, and up to þ48 months after the last dose of
RTX were retrieved through case report forms. Demographic data,
clinical history, IgG, IgM, and IgA levels, and peripheral blood
lymphocyte count ﬂow cytometry (CD3þ, CD4þ, CD8þ, CD19þ,
CD16/56þ) were included. Genetic analysis and B-/T-cell extended
phenotypic analyses were performed according to clinician decision
and/or technical availability. Diagnosis of PID was made when
pathogenic mutations were found in genes associated with PIDs or
according to the clinical phenotype, classifying patients as reported
by the 2017 IUIS Phenotypic Classiﬁcation.31
The study protocol conforms to the ethical guidelines of the 1979
Declaration of Helsinki as reﬂected in a priori approval by the
institution’s human research committee. Institutional Ethical
Committee of the University of Rome Tor Vergata approved the
study.
Definitions
Transient hypogammaglobulinemia was deﬁned as low IgG levels
(<2 SD for age) with subsequent normalization of IgG values and/or
discontinuation of immunoglobulin replacement for those patients
who started immunoglobulin replacement therapy. PH was deﬁned
as IgG less than 2 SD for age after RTX and no subsequent spon-
taneous recovery at last available follow-up more than 12 months
after RTX. IgA and IgM deﬁciencies were considered to be present
when these immunoglobulin levels were less than 2 SD for age.32
T- and B-cell immune reconstitution was deﬁned by absolute
lymphocyte subset counts within normal range for age at last
follow-up.33
TABLE I. Clinical and demographic features of 53 children treated
with RTX for autoimmune cytopenia
Feature Value (N [ 53), n (%)
Diagnosis
ITP 36 of 53 (69%)
AHA 13 of 53 (24%)
ES 4 of 53 (7%)
Age at diagnosis (mo)
Median 72
Range 1-204
Age at RTX (mo)
Median 114
Range 2-208
Sex
Male 31 of 53 (58%)
Female 22 of 53 (42%)
RTX doses
Median 4 doses
Range 1-16
<4 doses 8 of 53 (15%)
4 doses 38 of 53 (73%)
>4 doses 7 of 53 (12%)
Pre-RTX therapies
HD-IVIG only 3 of 53 (5%)
CS only 2 of 53 (4%)
CS þ MMF 1 of 53 (2%)
CS þ sirolimus 1 of 53 (2%)
HD-IVIG þ CS only 33 of 53 (60%)
HD-IVIG þ CS þ other* 13 of 53 (27%)
TPO agonist 5 of 53 (9%)
MMF 5 of 53 (9%)
Azathioprine 2 of 53 (4%)
Immunoglobulin anti-IgD 2 of 53 (4%)
Cyclophosphamide 2 of 53 (4%)
Methotrexate 1 of 53 (2%)
Cyclosporin 1 of 53 (2%)
Sirolimus 1 of 53 (2%)
Splenectomy 1 of 53 (2%)
Autoimmunity
Autoimmune thyroiditis 6 of 53 (11%)
Autoimmune neutropenia 2 of 53 (4%)
Celiac disease 1 of 53 (2%)
Autoimmune hepatitis 1 of 53 (2%)
Crohn disease 1 of 53 (2%)
Anti-ADAMTS13 syndrome 1 of 53 (2%)
Infections
Hospitalization 7 of 53 (12%)
Recurrent respiratory infections 8 of 53 (15%)
CS, Corticosteroid; HD-IVIG, high-dose intravenous immunoglobulin; MMF,
mycophenolate mofetil; TPO, thrombopoietin.
*Patients could receive more than 1 additional therapy after HD-IVIG and CS;
therefore, there is no correspondence with the total of patients.
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Patients’ features and demographic characteristics were included
in descriptive statistics. Log-rank test was performed to compare
B-cell immune reconstitution kinetics. Continuous variables were
expressed as median and range and were compared between groupsusing Student t test. The threshold for statistical signiﬁcance was set
to a P value less than .05. Univariate analysis using the Fisher exact
test was used to investigate potential risk factors for PH. Variables
that showed a signiﬁcant (P < .05) association with outcome in
univariate analysis were included in logistic regression model for
multivariate analysis. Data analysis and statistics were performed
using Prism GraphPad software, version 6 (GraphPad Software, Inc,
La Jolla, Calif) and Epi Info 7 software (Centers for Disease Control
and Prevention, Atlanta, Ga).
RESULTS
Patients’ characteristics
We enrolled 53 children who received RTX in the study
period. Data on pre-RTX immunoglobulin levels and B cells
were available for 40 of 53 (76%) and 39 of 53 (73%) patients,
respectively. No determination was available for 6 patients, and 7
patients had an IgG level of greater than 2000 mg/dL, but levels
were considered unreliable because they were investigated close
to infusion of high-dose intravenous immunoglobulins.
Demographic characteristics and clinical features of the study
population are presented in Table I. All patients received at least
1 front-line therapy before RTX. Most children (33 of 53 [60%])
were refractory to both steroids and high-dose intravenous
immunoglobulins, and RTX was used as a third-line treatment.
Conversely, additional immunosuppressive drugs were adminis-
tered after high-dose intravenous immunoglobulins and/or ste-
roids in 10 patients: a single agent was used in 5 patients,
whereas 4 children and 1 child received 2 and 3 immunosup-
pressive drugs, respectively. Finally, a thrombopoietin analogue
(romiplostim) was used before RTX in 5 patients. Most of the
patients received a single course of RTX (4 weekly doses at 375
mg/m2/dose), according to international guidelines.1,6 However,
a small proportion (12%) of patients required more than 1
treatment cycle, up to 4 courses. Eight patients had a history of
recurrent respiratory tract infections, and 7 patients required
admission for infections (range, 1-3 hospitalizations) before
RTX. Considering autoimmune manifestations (other than ITP,
AHA, and ES), 23% (12 of 53) of the patients had a history of
concomitant autoimmune disease at the time of diagnosis or
during follow-up: 6 patients presented with autoimmune
thyroiditis, 2 with autoimmune neutropenia, 1 with autoim-
mune hepatitis, 1 with celiac disease, 1 with Crohn disease, and 1
with anti-ADAMTS13 antibody syndrome. Genetics for PID
was performed for 4 patients before RTX use. The WAS gene
was sequenced in 1 patient, XIAP and SH2D1A genes in other 2
patients, and autoimmune lymphoproliferative
syndromeecausing genes (FAS, FAS ligand, Caspase 8, and
Caspase 10) were tested in 1 patient. All patients were wild-type
for the analyzed genes. No patient presented a signiﬁcant family
history for PIDs.
Hypogammaglobulinemia and immune reconstitution
after RTX
After the last RTX course, patients were followed up for 30
months (mean, range 12-48 months). Twenty-nine patients
(55%) did not develop hypogammaglobulinemia after RTX. A
transitory drop in IgG levels was observed in 7 patients (13%),
who started immunoglobulin but subsequently discontinued the
treatment and recovered IgG levels within the ﬁrst year after
RTX. However, 16 of 53 (30%) children persistently needed
immunoglobulin to maintain adequate IgG levels more than 12
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FIGURE 1. Cumulative incidence of PH during follow-up in 53
children treated with RTX.
TABLE II. Comparison of pre-RTX vs post-RTX immunoglobulin
levels in 36 children with no or transient hypogammaglobulinemia
No.
IgG (mg/dL) IgM (mg/dL) IgA (mg/dL)
Pre-RTX Post-RTX Pre-RTX Post-RTX Pre-RTX Post-RTX
1 804 903 115 21 73 53
2 — 659 — — — —
3 796 816 41 29 57 75
4 1800 1540 251 157 271 277
5 1280 1230 44 27 253 233
6 — 630 — 114 — 56
7 1158 880 100 77 259 230
8 — 563 — 21 — 71
9 960 850 78 66 156 100
10 239 494 86 47 36 33
11 949 919 101 161 105 94
12 748 644 116 61 140 143
13 765 816 108 37 67 134
14 1850 1760 248 34 122 46
15 1250 1180 114 71 107 119
16 1630 1310 108 57 112 110
17 1510 1370 178 98 78 70
18 960 896 99 53 24 22
19 1096 984 252 69 16 106
20 1482 607 128 37 137 96
21 1663 1442 98 17 <5 <5
22 1040 1030 146 187 118 141
23 765 655 97 — 83 —
24 1795 1440 66 41 97 118
25 696 518 86 42 107 66
26 1034 1028 116 50 140 173
27 626 695 41 — 155 —
28 — 1260 31 44 50 47
29 1230 1280 165 33 67 45
30 — 975 88 27 337 209
31 — 808 134 76 100 110
32 855 752 66 34 200 212
33 519 700 35 31 38 98
34 1070 1030 133 50 94 99
35 — 916 158 24 49 7
36 376 790 79 92 80 103
Values in bold: Immunoglobulin <2 SD of age-matched controls; cells with em
dash: missing data.
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(<2 SD) for age at last follow-up although he did not receive
substitutive immunoglobulins because of parental decision, more
than 1 year after the treatment. These patients (17 of 53 [32%])
were considered affected by PH, whereas children with normal
IgG levels at last follow-up more than 12 months after RTX were
deﬁned as patients without PH (Figure 1). Nearly half the pa-
tients with PH (8 of 17 [47%]) started immunoglobulin within 6
months after RTX, whereas immunoglobulin treatment was
initiated at 12 months or later in 8 patients.
The incidence of IgA and IgM deﬁciency was also investi-
gated. A similar proportion of patients had IgM levels less than 2
SD for age in the 2 groups before RTX (11% [4 of 36] vs 17%
[3 of 17]) (Tables II and III). However, looking at patients with
normal IgM levels at enrollment, new-onset hypo-IgM during
follow-up was more frequent in children with PH (10 of 11
[91%]) than in the group without PH (8 of 29 [28%]). Timing
to observe IgM normalization was also delayed in children with
PH (log-rank hazard ratio, 0.12; 95% CI, 0.07-0.35; P < .0001;
Figure 2, A), but it occurred within 12 months after RTX in
children without PH. Prevalence of low IgA levels for age was
comparable at baseline in both groups (8% [3 of 36] vs 23%
[4 of 17]), but after RTX patients with normal IgA levels more
frequently developed IgA deﬁciency in the PH group (80%
[8 of 10]) than in the non-PH group (7% [2 of 30]). Signiﬁ-
cantly, slower IgA recovery occurred after RTX in children with
PH (hazard ratio, 0.18; 95% CI, 0.05-0.22; P < .0001;
Figure 2, B) compared with children without PH, who
normalized IgA levels within 12 months from treatment. Finally,
new-onset combined isotype deﬁciency (IgM and IgA levels
below 2 SD for age) was signiﬁcantly more frequent (7 of 17
[41%] vs 1 of 36 [3%]; P < .001) in patients with PH.
B-cell immune reconstitution was evaluated during follow-up
at 5 time points. In the PH group, 6 of 17 patients (35%) did
not show complete B-cell recovery; in contrast 34 of 36 (94%)
patients with normal IgG levels at last follow-up had normal B
cells after RTX. Notably, B-cell immune reconstitution was
signiﬁcantly delayed in the PH group (hazard ratio, 0.55; 95%CI, 0.2-0.65; P < .05), whereas 83% of the patients without PH
already normalized B-cell count at 12 months after RTX
(Figure 3). B-cell memory subsets were investigated in 6 patients
with PH, and 5 had low (<2%) CD27þIgMIgD switched-
memory B (smB) cells.
Risk factors for persistent hypogammaglobulinemia
We compared the baseline clinical and immunologic charac-
teristics of children with PH vs children without PH (Table IV).
Median pre-RTX IgA and IgM levels were lower in the PH
group (48 mg/dL vs 103 mg/dL and 62 mg/dL vs 105 mg/dL,
respectively). A younger age at diagnosis of autoimmune cyto-
penia was observed in patients with PH (51 vs 116 months),
whereas no signiﬁcant differences were found when age at
treatment, B- and T-lymphocyte counts, and IgG levels at
enrollment were compared. Univariate analysis showed that a
TABLE III. Comparison of pre-RTX immunoglobulin levels with
post-RTX immunoglobulin levels in 17 children with PH
No.
IgG (mg/dL) IgM (mg/dL) IgA (mg/dL)
Pre-RTX Post-RTX Pre-RTX Post-RTX Pre-RTX Post-RTX
1 1360 96 67 5 321 8
2 331 462* 6 25 23 <8
3 795 254 73 5 106 <6
4 521 760* 44 7 92 23
5 — 285 — 5 — 13
6 1720 442 81 1 52 17
7 1260 291 87 7 44 14
8 432 580* 43 <5 36 <6
9 1280 867* 41 28 59 76
10 327 118 43 50 28 58
11 1520 278 56 19 15 <5
12 418 272 16 39 58 19
13 1650 451 80 11 88 31
14 — 608* — 3 — 69
15 — 210 — <17 — <5
16 843 258 91 36 114 110
17 523 321 41 8 52 28
IVIG, Intravenous immunoglobulin.
Values in bold: Immunoglobulin <2 SD of age-matched controls; box with em dash:
missing data.
*Immunoglobulin values after IVIG replacement therapy.
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FIGURE 2. (A) Log-rank analysis for comparison of IgM normali-
zation post-RTX in children with PH vs children with normal IgG
levels (non-PH). (B) Log-rank analysis for comparison of IgA
normalization post-RTX in children with PH vs children with
normal IgG levels (non-PH).
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OTTAVIANO ETAL 5diagnosis of AHA/ES vs ITP diagnosis was signiﬁcantly associ-
ated with PH (Table V). Moreover, patients in whom the
cytopenia resolved after B-cell depletion were more frequently
affected by PH (59% vs 28%; P < .05). Also, the occurrence of
autoimmune manifestations (other than the original autoim-
mune cytopenia) correlated with PH. However, total RTX ad-
ministrations and use of additional immunosuppressants were
not associated with a higher risk of PH. On multivariate analysis,
AHA/ES and response to RTX were independently associated
with occurrence of sustained IgG deﬁciency (Table V).
Clinical phenotype and diagnosis of PID
No signiﬁcant infections were documented after treatment
with RTX for patients who maintained normal IgG levels during
follow-up. In contrast, in the PH group post-RTX infections
requiring hospitalization were reported for 5 of 17 patients
(29%). Four patients presented with multiple upper and lower
airway infections (>4 episodes/y), requiring antibiotic therapy.
Peripheral blood EBV reactivation was documented in 2 pa-
tients. Also, 1 patient presented with Pneumocystis jirovecii
pneumonia. Finally, 1 patient suffered from perianal bacterial
lesions. Noninfectious complications included EBV-driven
lymphoma, additional autoimmune manifestations, and spleno-
megaly. Among the 17 patients with PH, 9 (53%) were even-
tually diagnosed as suffering from PID. In 2 children with PH,
next-generation sequencing panel analysis allowed the identiﬁ-
cation of a pathogenic homozygous mutation in the DCLRE1C
gene and a heterozygous gain-of-function mutation in the
PIK3CD gene. Other 5 patients presented with the clinical
picture of patients with CVID (hypogammaglobulinemia,
recurrent infections, IgA and IgM deﬁciency, low smB cells, and
impaired vaccine responses) and 2 patients had a predominant
antibody deﬁciency (PAD), not better speciﬁed (no informationwas available on vaccine responses and B-cell subsets). Detailed
phenotype and immunologic abnormalities of these 9 patients
are presented in Table VI. Single genes (TACI, PRF1, and WAS)
and next-generation sequencing panels for multiple genes asso-
ciated with hypogammaglobulinemia were analyzed in 6 patients,
but no abnormalities were observed. Pre-RTX immunologic
status was not available in 1 patient, and no data on B cells were
available at enrollment for another patient, who, however, had a
normal immunoglobulin level before starting anti-CD20 mAb.
Six patients had normal IgG and B cells before RTX. Only 2
patients already presented with low immunoglobulins and/or low
lymphocyte counts, although they were extensively treated with
high-dose steroids (patient 1 and patient 6 in Table VI).DISCUSSION
RTX is considered an effective treatment for several autoim-
mune diseases with an acceptable safety proﬁle. However, some
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FIGURE 3. Log-rank analysis for comparison of B-cell recovery in
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TABLE IV. Patients’ features and pre-RTX immunologic phenotype comparison of children with PH vs children without PH
Feature PH [ 17 Non-PH [ 36 P value
Age at diagnosis, mo (range) 51 (1-167) 116 (4-204) <.01
Age at RTX, mo (range) 95 (2-180) 116 (6-208) .15
IgG (mg/dL), median (range) 659 (327-1360) 997 (239-1850) .1
IgA (mg/dL), median (range) 48 (6-321) 103 (4-337) <.01
IgM (mg/dL), median (range) 62 (16-252) 105 (31-251) <.01
CD3þ/mm3, median (range) 1330 (195-2587) 1437 (600-3912) .3
CD19þ/mm3, median (range) 282 (90-588) 465 (129-2000) .2
Bold characters represent signiﬁcant or close to signiﬁcance cut-off values.
TABLE V. Risk factors associated with the development of PH in children treated with RTX by Fischer exact test analysis and logistic
regression model for variables with significant association with PH development in univariate analysis
Risk factor
Univariate analysis Logistic regression
PH [ 17 Non-PH [ 36 OR (95% CI) P value OR (95% CI) P value
AHA/ES 59% (10 of 17) 17% (7 of 36) 5.9 (1.7-21) <.01 5.5 (1.1-27) <.05
Age at diagnosis < median 65% (11 of 17) 39% (14 of 36) 2.9 (0.9-10) .14
Age at RTX < median 59% (10 of 17) 39% (14 of 36) 2.2 (0.7-6) .2
RTX doses > 4 24% (4 of 17) 8% (3 of 36) 2 (0.4-10) .4
Response to RTX 59% (10 of 17) 28% (10 of 36) 3.7 (1.1-12) <.05 4.9 (1.6-24) <.05
Autoimmunity 41% (7 of 17) 14% (5 of 36) 4.34 (1.1-16) <.05 4.8 (0.8-28) .07
Additional IS* 29% (5 of 17) 14% (5 of 36) 1.2 (0.4-6) .7
HD-IVIG, High-dose intravenous immunoglobulin; IS, immunosuppressants; OR, odds ratio.
Bold characters represent signiﬁcant or close to signiﬁcance cut-off values.
*In addition to steroids and HD-IVIG.
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extensively detailed long-term follow-up of 53 children treated
for autoimmune cytopenia with mAb anti-CD20, who experi-
enced a 32% prevalence of sustained hypogammaglobulinemia.
We showed that prolonged B-cell depletion was associated with
IgA and IgM deﬁciency for a signiﬁcant proportion of patients
and IgG deﬁciency, overall leading to clinical or genetic diagnosis
of PID in about 20% of treated children.Immunologic workup is not routinely performed before the
administration of RTX. Indeed, more than 80% of patients
treated with anti-CD20 mAb for autoimmune diseases are not
screened for immunoglobulin deﬁciency and the risk of hypo-
gammaglobulinemia is not consistently assessed during follow-
up. However, when IgG levels are monitored, the prevalence
of new-onset hypogammaglobulinemia can be signiﬁcant
(w20%).34 The lack of standardized follow-up in clinical studies
and the use of prophylactic immunoglobulin replacement ther-
apy in the ﬁrst months after treatment limit the assessment of
hypogammaglobulinemia. Studies in adults with autoimmune
cytopenia treated with RTX reported an incidence of 6% of
severe hypogammaglobulinemia,9 but data on children are
lacking. Rao et al12 only reported that the nadir of IgG after anti-
CD20 administration in children with ITP or AHA is reached at
12 months, but they did not report the proportion of patients
with IgG levels less than 2 SD for age and data on longer follow-
up. The extended follow-up of our study could have facilitated
the diagnosis of late-occurring hypogammaglobulinemia: indeed,
for half the patients with PH, low IgG levels were ﬁrst observed
more than 12 months after treatment. This suggests that long-
term follow-up is needed to assess the true incidence ofpost-RTX hypogammaglobulinemia.
We showed that PH is usually followed by a drop in other
immunoglobulin isotype levels and when IgA and IgM levels
remain low after 12 months, post-RTX spontaneous improve-
ment is unlikely, suggesting a potential impaired maturation of
immunoglobulin-producing cells. This was also suggested by the
low smB-cell percentages documented in some patients with PH
(5 of 17 [29%]), resembling the immunologic phenotype of
TABLE VI. Clinical and immunologic features of patients with PH and final diagnosis of PID
Patient no. Pre-RTX phenotype Post-RTX clinical phenotype Post-RTX immune phenotype Final diagnosis
1 AHA, 2 y Follow-up 36 mo ARTEMIS
IgG: 331 mg/dL Proteus sepsis, EBV-driven Burkitt lymphoma IgG: 666* mg/dL
IgA: 6 mg/dL CMV reactivation IgA: <8 mg/dL
IgM: 23 mg/dL ITP IgM: 25 mg/dL
CD19þ: 315/mm3 CD19þ: 110/mm3
CD3þ: 200/mm3 CD3þ: 3256/mm3
CD3þ/CD4þ: 101/mm3 CD3þ/CD4þ: 285/mm3
CD3þ/CD8þ: 76/mm3 CD3þ/CD8þ: 2320/mm3
2 AHA, 1.3 y Follow-up 36 mo APDS
IgG: 521 mg/dL IgG: 1200* mg/dL
IgA: 44 mg/dL IgA: 23 mg/dL
IgM: 92 mg/dL IgM: 7 mg/dL
CD19þ: 295/mm3 CD19þ: 306/mm3
CD3þ: 2587/mm3 CD3þ: 1453/mm3
CD3þ/CD4þ: 1433/mm3 CD3þ/CD4þ: 783/mm3
CD3þ/CD8þ: 1013/mm3 CD3þ/CD8þ: 545/mm3
smB cells: 1.3%
3 ITP, 10 y Follow-up 48 mo CVID
IgG: 1360 mg/dL Recurrent RTI IgG: 701* mg/dL
IgA: 321 mg/dL Pneumocystis pneumonia IgA: 8 mg/dL
IgM: 67 mg/dL IgM: 5 mg/dL
CD19þ: 269/mm3 CD19þ: 337/mm3
CD3þ: 1380/mm3 CD3þ: 1526/mm3
CD3þ/CD4þ: 515/mm3 CD3þ/CD4þ: 550/mm3
CD3þ/CD8þ: 718/mm3 CD3þ/CD8þ: 930/mm3
smB cells: 0%
Absent vaccine responses
4 ITP, 7 y Follow-up 48 mo CVID
IgG: 795 mg/dL Recurrent RTI IgG: 417* mg/dL
IgA: 73 mg/dL Splenomegaly IgA: <6 mg/dL
IgM: 106 mg/dL Bronchiectasis IgM: 5 mg/dL
CD19þ: 320/mm3 Ground-glass changes at CT scan CD19þ: 47/mm3
CD3þ: 1275/mm3 CD3þ: 1059/mm3
CD3þ/CD4þ: 784/mm3 CD3þ/CD4þ: 532/mm3
CD3þ/CD8þ: 415/mm3 CD3þ/CD8þ: 469/mm3
smB cells: 0.7%
Transitional B cells: 14.6%
Absent vaccine responses
5 AHA, 1.2 y Follow-up 36 mo PAD
IgG: 432 mg/dL Autoimmune hepatitis IgG: 700* mg/dL
IgA: 36 mg/dL IgA: <6 mg/dL
IgM: 43 mg/dL IgM: <5 mg/dL
CD19þ: 356/mm3 CD19þ: 0/mm3
CD3þ: 2137/mm3 CD3þ: 973/mm3
CD3þ/CD4þ: 1276/mm3 CD3þ/CD4þ: 712/mm3
CD3þ/CD8þ: 861/mm3 CD3þ/CD8þ: 171/mm3
6 AHA, 10 y Follow-up 36 mo PAD
IgG: 1260 mg/dL Recurrent RTI (Pseudomonas; Staphylococcus aureus) IgG: 530* mg/dL
IgA: 44 mg/dL Perianal abscess IgA: 10 mg/dL
IgM: 87 mg/dL (Citrobacter freundii; Enterococcus gallinarum) IgM: 36 mg/dL
CD19þ: 114/mm3 Salmonella spp infection CD19þ: 138/mm3
CD3þ: 430/mm3 Lymphoproliferation CD3þ: 1035/mm3
CD3þ/CD4þ: 318/mm3 CD3þ/CD4þ: 725/mm3
CD3þ/CD8þ: 94/mm3 CD3þ/CD8þ: 380/mm3
(continued)
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TABLE VI. (Continued)
Patient no. Pre-RTX phenotype Post-RTX clinical phenotype Post-RTX immune phenotype Final diagnosis
7 ITP, 11.6 y Follow-up 24 mo CVID
IgG: 772 mg/dL Chronic rhinitisEBV chronic reactivation IgG: 313* mg/dL
IgA: 15 mg/dL IgA: <5 mg/dL
IgM: 56 mg/dL IgM: 14 mg/dL
CD19þ: ND CD19þ: 406/mm3
CD3þ: ND CD3þ: 1525/mm3
CD3þ/CD4þ: ND CD3þ/CD4þ: 684/mm3
CD3þ/CD8þ: ND CD3þ/CD8þ: 656/mm3
Memory B cells: 3%
Transitional B cells: 15.7%
Plasma cells: 0.6%
8 AHA, 14 y Follow-up 48 mo CVID
IgG: ND Recurrent RTIAnti-ADAMTS13 syndrome IgG: 210* mg/dL
IgA: ND IgA: <7 mg/dL
IgM: ND IgM: <17 mg/dL
CD19þ: ND CD19þ: 170/mm3
CD3þ: ND CD3þ: 1353/mm3
CD3þ/CD4þ: ND CD3þ/CD4þ: 493/mm3
CD3þ/CD8þ: ND CD3þ/CD8þ: 816/mm3
smB cells: 0.5%
9 AHA, 4.7 y Follow-up 24 mo CVID
IgG: 843 mg/dL IgG: 92* mg/dL
IgA: 114 mg/dL IgA: 110 mg/dL
IgM: 91 mg/dL IgM: 36 mg/dL
CD19þ: 336/mm3 CD19þ: 207/mm3
CD3þ: 1024/mm3 CD3þ: 1752/mm3
CD3þ/CD4þ: 400/mm3 CD3þ/CD4þ: 873/mm3
CD3þ/CD8þ: 528/mm3 CD3þ/CD8þ: 712/mm3
smB cells: 2%
Absent vaccine response
APDS, Activated PI3K delta syndrome; CMV, cytomegalovirus; CT, computed tomography; ND, not determined; RTI, respiratory tract infection.
*Patients on immunoglobulin replacement therapy at last follow-up.
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prevalence of impaired B-cell recovery (35%), which was already
evident at 12 months post-RTX and preceded overt PH.
Therefore, patients with a low B-cell count at 12 months but
normal IgG level should be carefully monitored because PH may
occur afterwards. However, even some patients with PH with
normal B cells required long-term immunoglobulin replacement
therapy. These children could present an intrinsic defect in
smB-cell maturation, or hypogammaglobulinemia could be the
result of an impaired cognate TH-B-cell interaction. B-cell
perturbation induced by RTX could unbalance T- and
B-lymphocyte homeostasis, resulting in ineffective immuno-
globulin production.
We also aimed to deﬁne a speciﬁc clinical phenotype that
could help in identifying children at a higher risk of PH after
RTX. Children with PH were signiﬁcantly younger than patients
with normal IgG levels. Even though the occurrence of more
severe disease in children with PH cannot be excluded, another
possible explanation is that autoimmune cytopenia could repre-
sent the ﬁrst manifestation of an underlying immune impairment
that was not fully discernible at the time of thrombocytopenia
and/or hemolytic anemia onset. Conversely, in older children
with autoimmune cytopenia, the presence of other clinical and/or immunologic features might facilitate the diagnosis of PID
that per se could exclude them from the study. Pre-RTX IgG and
lymphocyte subsets were not signiﬁcantly different in patients
with PH. However, comparison of absolute lymphocyte counts
can be difﬁcult because most of the patients were extensively
treated with steroids and/or other immunosuppressive drugs. IgA
and IgM levels were signiﬁcantly lower in the PH group, prob-
ably reﬂecting younger age at diagnosis in this group, because
patients with immunoglobulin levels less than 2 SD for age
before treatment were equally distributed in the 2 groups.
Moreover, some patients were treated with RTX at a very young
age (<4 years), and it was not possible to discern children with
potential transient hypogammaglobulinemia of infancy. How-
ever, our study mirrors a clinical practice experience, where
unfortunately extensive immunologic workup is not always
performed in children with refractory autoimmune cytopenia.
Interestingly, we found a signiﬁcantly higher risk of PH in pa-
tients with AHA or ES. Patients with PID present a higher
incidence of autoimmune cytopenia, especially AHA and ES.
Fischer et al36 reported that more than 25% of PIDs have 1 or
more autoimmune manifestations, and the risk of autoimmune
cytopenia is estimated to be 120-fold higher than in the general
population, indeed, up to 830-fold for autoimmune hemolytic
J ALLERGY CLIN IMMUNOL PRACT
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ﬁndings, because 9 patients with PH in our cohort were even-
tually diagnosed with a PID, supporting the hypothesis that PH
after RTX is part of a PID phenotype. The higher rate of
response to RTX in the PH group supports the hypothesis that
B-cell depletion per se uncovers intrinsic immunologic defects.
Indeed, constitutive immune system impairments were observed
regardless of the cumulative exposure to anti-CD20 (total doses)
or additional immunosuppression. However, autoimmune
cytopenia also resolved in patients with PH who recovered B
cells. Extensive analysis of B-cell subsets could help to clarify the
mechanism of response to anti-CD20 mAb in children. Taken
together, these observations suggest that patients who experience
AHA or ES at a younger age and improvement/resolution of
cytopenia after B-cell depletion need to be investigated exten-
sively. Incomplete B-cell reconstitution at 12 months should
encourage prolonged immunoglobulin level monitoring, B-cell
subset analysis, and prompt clinical follow-up.
During follow-up, signiﬁcant infectious and noninfectious
complications were documented in the group of patients with
PH, as part of complex clinical and immunologic phenotypes
that are not usually reported in children treated with RTX.
Speciﬁcally, a genetic diagnosis of 2 patients with PID and a
clinical diagnosis of 7 patients with CVID or PAD were made.
Seven of 9 patients did not present immunologic or clinical
features before starting RTX, which could suggest an underlying
immunologic defect. This could be attributed to the young age of
the treated children, when immunologic defects were not easily
discernible. Moreover, for all patients there was no suggestive
history of PID before starting RTX, whereas infectious compli-
cations became relevant in the ﬁrst years after treatment. This
supports the hypothesis that B-cell depletion can alter immune
system homeostasis of patients with a constitutive immunologic
defect that was not appreciable before. However, because our
data are partially retrospective, some limitations do not allow
ﬁnal conclusions and the impact of RTX on unveiling subclinical
immunodeﬁciency needs to be carefully considered. Because the
diagnosis of CVID and PAD was based on clinical criteria, it was
not possible to exclude the potential iatrogenic effect of RTX to
explain PH. However, the complex immunologic and clinical
phenotype of these patients is unlikely due to RTX use in chil-
dren with autoimmune cytopenia and can help to discern pa-
tients with PID from secondary immunodeﬁciency.
Furthermore, although the additional effect of immunosup-
pressive treatment might contribute to delayed B-cell immune
reconstitution, the only patient with PAD/CVID diagnosis who
received cyclophosphamide, azathioprine, and cyclosporin before
RTX never recovered B cells at 36 months after RTX, in the
presence of normal T cells. Indeed, altered B-cell recovery is
more likely due to an intrinsic B-cell defect, because anti-CD20
mAb cannot target early B-cell precursors that lack CD20
expression, rather than a direct prolonged effect of RTX or a
combination of immunosuppressive treatments. A full and
exhaustive immunologic workup, including immunoglobulins,
lymphocyte subsets, and speciﬁc vaccine antibody responses,
should be performed in all patients before starting RTX to
discern the occurrence of new-onset hypogammaglobulinemia
from preexisting immunologic defects and to evaluate other
second-line treatments. During follow-up all immunoglobulin
isotypes should be investigated and whenever patients develop
immunoglobulin deﬁciency or other immunologic defects,extended analysis of lymphocyte subsets (ie, smB cells), vaccine
responses, and genetic analysis are recommended for the early
identiﬁcation of those children presenting with autoimmune
disease but with an underlying PID.
CONCLUSIONS
This is the largest cohort of children with autoimmune
cytopenia with PH treated with RTX. We identiﬁed a speciﬁc
subgroup of patients who should require a close and prolonged
follow-up to achieve an early diagnosis of PID. These data should
encourage a careful follow-up of these patients, at least until full
immune reconstitution is achieved, and prospective studies
should be encouraged to further explore the role of B-cell
perturbation induced by RTX.
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